🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to scientists.

An International Challenge

Cases of gonorrhoea are on the rise globally, with data suggesting in excess of 82 million instances each year. Notably increased rates are observed in the African continent and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the context of rising global incidence, escalating drug resistance and the extremely scarce therapeutic options presently on offer.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Gain Authorization

One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in mid-December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers believe that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This medication, which is employed against urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone marks a major breakthrough in the management of superbug gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Clinical Trial Outcomes and Global Access

As per data released by a major medical journal, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which combines an injection and a pill. The trial involved nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the ability to register and commercialise the drug in many regions with limited resources.

Medical professionals on the front lines have voiced positive views. Access to a single-dose, oral treatment like this is seen as a "critical tool" for public health efforts. This is considered essential to lessen the impact of the illness for patients and to stop the proliferation of highly drug-resistant gonorrhoea globally.